In today’s briefing:
- Imugene (IMU AU): Pipeline Progresses; Capital Injection to Extend Cash Runway to Late 2025
Imugene (IMU AU): Pipeline Progresses; Capital Injection to Extend Cash Runway to Late 2025
- Imugene Ltd (IMU AU) announced dosing of the first Australian patient in the Phase 1b clinical trial of its allogeneic CAR T-cell therapy azer-cel in diffuse large B-cell lymphoma.
- Azer-Cel is one of the few allogeneic CAR T-cell therapies currently being evaluated in Australia. Azer-cel has potential revenue opportunity of $2.5B per annum.
- Imugene intends to raise A$46M through convertible bonds and warrants. Cost savings initiatives provide cash runway into late 2025. Early-stage pipeline and fund raising requirement make Imugene a risky bet.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
